Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Galapagos NV ADR (NQ: GLPG )

29.52 +1.13 (+4.00%)
Streaming Delayed Price Updated: 3:44 PM EDT, Aug 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Galapagos NV ADR

< Previous 1 2 3 4 Next >
Why Trip.com Group Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Major Investor Says Galapagos Is 'Undervalued,' Plans To Push On Company's 'Performance' And 'Strategic Opportunities'
Galapagos stock rises as EcoR1 Capital discloses a 9.9% stake and plans to engage on business and governance. Investor sees shares as deeply undervalued despite challenges, with new focus on CAR-T... 
Via Benzinga
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
The company is gearing up to rival giants Gilead and Novartis with a potentially decentralized CAR-T process. 
Via Investor's Business Daily
Exposures Product Safety
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
Via Benzinga
8 Analysts Have This to Say About Galapagos
Via Benzinga
Where Galapagos Stands With Analysts
Via Benzinga
JP Morgan Maintains Neutral Rating for Galapagos: Here's What You Need To Know
Via Benzinga
Earnings Outlook For Galapagos
Via Benzinga
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
Via Benzinga
FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade
FDA approves Adaptimmune Therapeutics' Tecelra for unresectable or metastatic synovial sarcoma, a rare cancer near large joints. Tecelra, the first engineered cell therapy for solid tumors in the U.S.,... 
Via Benzinga
Exposures Product Safety
GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q2 2024
GLPG stock results show that Galapagos beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
GLPG Stock Earnings: Galapagos Beats EPS, Misses Revenue for Q1 2024
GLPG stock results show that Galapagos beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell... 
Via Newsfile
Earnings Preview For Galapagos
Via Benzinga
Where Galapagos Stands With Analysts
Galapagos (NASDAQ:GLPG) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst
BofA Securities downgrades Galapagos to underperform due to limited near-term catalysts and competitive challenges in crowded markets. 
Via Benzinga
Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline
From Frontier Medicines
Via GlobeNewswire
European Drugmaker Galapagos Collaborates With Biotech BridGene Biosciences To Develop Cancer Treatments
On Wednesday, BridGene Biosciences Inc. announced a strategic collaboration and licensing agreement with Galapagos NV (NASDAQ: GLPG). 
Via Benzinga
GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q3 2023
GLPG stock results show that Galapagos beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2023. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For May 8, 2023
Via Benzinga
BigCommerce, ContextLogic And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Galapagos' Blood Cancer Candidate Shows 100% Objective Response Rate In Relapsed/Refractory Patients
Via Benzinga
Why Galapagos Stock Is Falling Today
Galapagos NV (NASDAQ: GLPG) announced the topline results from the DIVERSITY Phase 3 trial of filgotinib during induction and maintenance treatment of biologic-naïve and biologic-experienced patients... 
Via Benzinga
Twitter Rolls Out 'Blue For Business,' Visa Pitches Auto-Payments On Ethereum Blockchain, Justin Bieber Slams H&M: Today's Top Stories
Benzinga 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 23, 2023
Via Benzinga
On A Mission As Top European Player, Galapagos Looks For Acquisition Targets
Galapagos NV (NASDAQ: GLPG) is reportedly looking for M&A deals with companies with products still in the preclinical or early stage of development. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 7, 2022
Upgrades 
Via Benzinga
After FDA, European Agency Limits Use Of Certain JAK Inhibitors Amid Safety Concerns
Via Benzinga
Expert Ratings for Galapagos
Over the past 3 months, 4 analysts have published their opinion on Galapagos (NASDAQ:GLPG) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
3 Biotech Stocks to Sell in October
These biotech stocks to sell are at a cross roads with their businesses with few growth catalysts ahead amid this turbulent market. 
Via InvestorPlace
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.